Biote CEO: Employers need to normalize women's health issues in the workforce

A survey by Biote reveals the impact of menopause on working women.

By Robin Robinson • March 14, 2022

Ultragenyx's CEO on building a 'next-gen' rare disease company

How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

By Kim Ribbink • March 9, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

From angel to operator: The unlikely journey of Endevica Bio's CEO

Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.

By Jared Whitlock • March 9, 2022

Woman of the Week: Genentech's Quita Highsmith

Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.

By Taren Grom • March 9, 2022

Horizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride

Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.

By Alexandra Pecci • March 8, 2022

Ramona Sequeira breaks PhRMA's glass ceiling

A few weeks ago, PhRMA, the industry’s largest trade group, announced that Sequeira has officially become chair of the organization’s board of directors. She is the first woman — and first woman of color — to take on the job.

By Taren Grom • March 7, 2022

Two key factors behind NYC's record-setting rise in healthcare funding

According to a new report, women’s and digital health led to an explosion in funding last year in NYC.

By Robin Robinson • March 7, 2022

Succeed when others fail: Avoiding 20% in investment waste during launch

Approximately 20% of pharma spend during launch is wasted. You can right-size spending during launch & across the lifecycle.

March 7, 2022

Are patients happy? This simple question could shake up clinical trials

The migration to DCTs is helping uncover critical gaps in patient experience.

By Kelly Bilodeau • March 4, 2022

Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started

The company’s CEO on the road ahead for AI capabilities in pharma.

By Meagan Parrish • March 4, 2022

Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter

With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.

By Taren Grom • March 2, 2022

The 2022 PharmaVoice 100 — new look, same drive for excellence

Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.  

By Taren Grom • Feb. 28, 2022

Reaching the rare: How can we best support and engage with the rare disease community during the pandemic?

How can we better understand the challenges defining the pandemic journey of a rare disease patient?

Feb. 28, 2022

Guadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues

A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company. 

By Robin Robinson • Feb. 25, 2022

Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo

Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.

By Taren Grom • Feb. 23, 2022

Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market

The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.

By Kelly Bilodeau • Feb. 23, 2022

Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler

Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.

By Taren Grom • Feb. 16, 2022

Winning buy-in from early stage biotech investors

The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.

By Taren Grom • Feb. 11, 2022

Industry executives on the milestone moments shaping pharma's future

Scientific, technological, and communication changes that are making a permanent impact on the industry.

By Taren Grom • Feb. 9, 2022

Innovation vs. invention

IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.

By Taren Grom • Feb. 9, 2022

Saniona's CEO on why it takes a village to develop treatments for a rare disease

Saniona built its village by first hiring a head of patient advocacy.

By Kim Ribbink • Feb. 8, 2022

Why 23andMe's first solo clinical trial is a big deal

It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come. 

By Taren Grom • Feb. 7, 2022

Home is where the trial is

Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials. 

By Kelly Bilodeau • Feb. 7, 2022

Pharma's pain points with AI

Looking beyond the buzz and at the challenges associated with AI.

By Meagan Parrish • Feb. 7, 2022

Ferring Pharmaceuticals president discusses the need for more funding in women's health research

Read why women's healthcare funding is such a challenge.

By Robin Robinson • Feb. 4, 2022